{
    "2018-01-03": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Merck's Keytruda Gets Approved for Bladder Cancer in Japan",
                "features": {
                    "keywords": [
                        "Keytruda",
                        "approved",
                        "bladder cancer",
                        "Japan"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "3 Stocks That Feel Like Microsoft in 1986",
                "features": {
                    "keywords": [
                        "stocks",
                        "Microsoft",
                        "1986"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Analysts’ Recommendations for Eli Lilly in December 2017",
                "features": {
                    "keywords": [
                        "analysts",
                        "recommendations",
                        "Eli Lilly",
                        "December 2017"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Analysts’ Estimates for Eli Lilly",
                "features": {
                    "keywords": [
                        "analysts",
                        "estimates",
                        "Eli Lilly"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}